Innate Pharma discontinued its phase 1/2 NK cell engager program IPH6501, ending the B-cell non-Hodgkin lymphoma study as part of a strategic pipeline prioritization. Innate had been evaluating IPH6501, a tetraspecific antibody-based natural killer cell engager, across the U.S., Australia, and France, with planning for up to 184 patients. The dose-escalation segment had already been completed, and Innate indicated the study data would be presented later in 2026. The decision follows earlier company moves—including workforce reductions and repositioning toward assets it described as highest-value—and reflects how selective NK and immune-engager programs are being triaged. Innate’s leadership highlighted alternative catalysts including lacutamab in phase 3 Sézary syndrome and monalizumab in phase 3 non-small cell lung cancer.